Drug General Information |
Drug ID |
D01AOI
|
Former ID |
DNC009140
|
Drug Name |
6-(piperidin-4-ylmethoxy)-2-naphthonitrile
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C17H18N2O
|
Canonical SMILES |
C1CNCCC1COC2=CC3=C(C=C2)C=C(C=C3)C#N
|
InChI |
1S/C17H18N2O/c18-11-14-1-2-16-10-17(4-3-15(16)9-14)20-12-13-5-7-19-8-6-13/h1-4,9-10,13,19H,5-8,12H2
|
InChIKey |
SHJHTXWKDLOBQS-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Sodium-dependent noradrenaline transporter |
Target Info |
Inhibitor |
[1]
|
Sodium-dependent dopamine transporter |
Target Info |
Inhibitor |
[1]
|
Sodium-dependent serotonin transporter |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
Dopaminergic synapse
|
Parkinson's disease
|
Cocaine addiction
|
Amphetamine addiction
|
Alcoholismhsa04726:Serotonergic synapse
|
NetPath Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
Adrenaline and noradrenaline biosynthesisP00001:Adrenaline and noradrenaline biosynthesis
|
Parkinson disease
|
Dopamine receptor mediated signaling pathwayP04373:5HT1 type receptor mediated signaling pathway
|
5HT2 type receptor mediated signaling pathway
|
5HT3 type receptor mediated signaling pathway
|
5HT4 type receptor mediated signaling pathway
|
Pathway Interaction Database
|
Alpha-synuclein signaling
|
Reactome
|
Na+/Cl- dependent neurotransmitter transportersR-HSA-442660:Na+/Cl- dependent neurotransmitter transporters
|
WikiPathways
|
Monoamine Transport
|
NRF2 pathway
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport
|
Dopaminergic Neurogenesis
|
Parkinsons Disease Pathway
|
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
|
Neurotransmitter Clearance In The Synaptic CleftWP727:Monoamine Transport
|
SIDS Susceptibility Pathways
|
Synaptic Vesicle Pathway
|
Serotonin Transporter Activity
|
References |
REF 1 | Bioorg Med Chem Lett. 2009 Apr 15;19(8):2329-32. Epub 2009 Feb 20.Design and optimization of selective serotonin re-uptake inhibitors with high synthetic accessibility. Part 1. |